An Evaluation of the Clinical Usability of the SCD411 Prefilled Syringe as a Proposed Biosimilar to US-licensed Eylea®
Latest Information Update: 11 Jun 2026
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion; Wet age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sam Chun Dang Pharm
Most Recent Events
- 08 Jun 2026 Status changed to completed.
- 03 Apr 2026 New trial record